ClinicalTrials.gg
Not yet recruitingNCT06664307GPP-USEUpdated Oct 29, 2024

Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis.

An observational study in Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) and Hepatic Cirrhosis, sponsored by Hospital Universitario Virgen Macarena. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Hospital Universitario Virgen Macarena · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Liver Cirrhosis with a site in Spain — 16 open to participants now, 20 under way, 3 of them phase 3. Liver Cirrhosis · Spain.

Planned enrollment
23rd of 26
35 · median 334
Started
2024
with 8 others
Observational
26 of 76
8 open now
Primary completion
2026-11
later than 5 of 19 live
Registered
71st of 76
by date

Among the 76 studies in Liver Cirrhosis with a site in Spain, this one is the 23rd largest by planned enrollment of the 26 observational ones that give a count, is one of 9 that started in 2024, is one of 26 observational ones, reaches primary completion later than 5 of the 19 other live ones, and was the 71st registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

16 of the 76 studies in Liver Cirrhosis with a site in Spain are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Liver Cirrhosis with a site in Spain, or all of them as a file.
02

Study summary

The development of Clinical significant PH (CSPH) is a major driver of complications. PPG is the strongest predictor of decompensation . The shortcomings of GPVH measurements and invasiveness has resulted in an area of unmet clinical need. Non-selective beta-blockers (NSBB) have demonstrated efficacy in reducing PH. However, this requires a second invasive procedure, and there is high interindividual variability in the hemodynamic response to NSBB. EUS-guided GPP measurement emerges as a more accurate, accessible and less invasive technique to potentially predict chronic hemodynamic response. The aim of this project is to assess the safety and efficacy of EUS-derived GPP measurement (EUS-GPP) in patients diagnosed with cirrhosis, to assess the acute hemodynamic response through EUS-derived GPP to intravenous propranolol administration in order to determine the patients who would benefit from NSBB treatment in primary prophylaxis to prevent decompensation using a strategy guided by EUS-GPP measurement.

Read the detailed description

Liver cirrhosis is a progressive disease with a continuum of compensated to decompensated stages. The development of portal hypertension (PH) and fibrosis are the primary pathophysiological processes in this clinical course. Clinical significant PH (CSPH) is a major driver of complications such as ascites and variceal bleeding. PPG is the strongest predictor of decompensation with a negative predictive value of 90% for PPG \< 10 mmHg. Non-selective beta-blockers (NSBB) have demonstrated efficacy in reducing PH and preventing variceal bleeding. The clinical efficacy of NSBB is based on a significant reduction in PPG, estimated by HVPG measurement. However, this requires a second invasive procedure, and there is high interindividual variability in the hemodynamic response to NSBB. Therefore, the development of tools to identify patients who are likely to benefit from beta-blockers is an unmet clinical need. In this regard, PPG measurement guided by EUS can potentially predict the chronic hemodynamic response, serving as a strategy to guide therapy and identify patients who can benefit from NSBB in a single hemodynamic study, substantially reducing the need for repeated measurements. The aim of this project is to assess the safety and efficacy of EUS-derived GPP measurement (EUS-GPP) in patients diagnosed with cirrhosis, to assess the acute hemodynamic response through EUS-derived GPP to intravenous propranolol administration in order to determine the patients who would benefit from NSBB treatment in primary prophylaxis to prevent decompensation using a strategy guided by EUS-GPP measurement.

The natural history of cirrhosis can be described as a continuum from a compensated phase to decompensation and liver failure, marked by the development of overt ascites (or pleural effusion with a serum ascites albumin gradient [>1.1 g/dl]), encephalopathy (West Haven grade >II), and variceal bleeding, with a rate of 5 to 7% per year. This decompensation results in higher mortality and a median survival of 2 years compared to 12 years in the compensated phase1.

The events defining decompensation are hepatic fibrosis and the development of portal hypertension as the main pathophysiological processes of this clinical course. It has been demonstrated that the hepatic venous pressure gradient (HVPG) is the strongest predictor of decompensation, with a negative predictive value of 90% for HVPG less than 10 mm Hg2.

Compensated cirrhosis can be divided into 2 stages, based on the absence or presence of clinically significant portal hypertension (CSPH). Clinically significant portal hypertension (CSPH) is the main driver of complications3-4 - such as the development of ascites or variceal bleeding. It is important to note that CSPH, diagnosed by a hepatic venous pressure gradient (HVPG) of ≥10 mmHg, may be present before the complications of portal hypertension develop.

In general, CSPH is present in around 50 to 60% of patients with compensated cirrhosis without varices5-6, while patients with varices typically have an HVPG of at least 10 mmHg3-4. Patients with an HVPG >12 mmHg are at risk of variceal bleeding7. The risk of hepatic decompensation and mortality increases at HVPG levels >16 mmHg8, and at >20 mmHg, there is a higher frequency of uncontrolled bleeding, early rebleeding, and bleeding-related death3-9-10.

Non-selective beta-blockers (NSBBs) have demonstrated their efficacy in reducing portal hypertension and their role in the primary and secondary prophylaxis of variceal bleeding in patients with cirrhosis. The reduction in hepatic venous pressure gradient by NSBBs is associated with a lower risk of variceal bleeding and ascites, along with other benefits including improvement in bacterial translocation and prevention of spontaneous bacterial peritonitis, which have positive effects on survival1,3,11,12,13,14,15.

Such treatment is highly effective, accessible, and can reduce the prevalence of HVPG and decompensation.

The clinical efficacy of NSBBs for preventing portal hypertension-related events largely relies on a significant decrease in the portal pressure gradient, i.e., the "response," estimated by measuring HVPG via hepatic vein catheterization. Reductions in HVPG of at least 10%-20% (depending on whether we consider primary or secondary prophylaxis) or below 12 mmHg indicate a chronic hemodynamic response to NSBB treatment associated with decreases in bleeding-related events, ascites, and portal hypertension, as well as improvements in survival16. However, assessing the HVPG response to NSBB treatment requires a second invasive procedure.

The main drawback of NSBBs is the significant interindividual variability in hemodynamic response, even within a specific stage of the disease; therefore, the development of tools to identify patients most likely to benefit from beta-blockade is an area of unmet clinical need. In this regard, measurements of HVPG before and after intravenous administration of an NSBB may help overcome these limitations and potentially predict chronic hemodynamic response. This approach could serve as a strategy to guide therapy and identify patients who may benefit from it in a single hemodynamic study, substantially reducing the need for repeated measurements17.

The prognostic role of an acute hemodynamic response to intravenous propranolol in primary18,19 and secondary prophylaxis19 has been evaluated by three previous studies, which have linked the value of acute response to predicting overall hepatic decompensation and subsequent decompensations in particular. These studies particularly highlight the relevance of assessing acute response as a tool for early risk stratification and estimating treatment efficacy during a single hemodynamic study, being more cost-effective and time-effective, as well as less invasive than two consecutive measurements of HVPG with and without NSBB treatment. Additionally, although the evolution of the underlying liver disease may also provide prognostic information and theoretically may strengthen the prognostic value of chronic hemodynamic response status20, it complicates the assessment of a potential benefit of NSBB therapy in the individual patient. This is particularly relevant in the context of treatment approaches guided by hemodynamic response, as applied in the PREDESCI study.

However, the shortcomings of HVPG measurements, such as invasiveness and cost, have raised the question of whether we can accurately identify CSPH through other modalities. Endoscopic ultrasound (EUS) enables comprehensive diagnosis and therapy in advanced liver disease. One of the techniques guided by EUS involves the measurement of the portal pressure gradient (PPG)21.

The determination of the hepatic venous pressure gradient (HVPG) allows for the assessment of portal hypertension and the issuance of an evolutionary risk based on its magnitude (Table 1). It is performed approximately and indirectly by interventional radiology, through catheterization and pressure measurement in the suprahepatic vein, and then inflating a balloon, assuming that the pressure obtained in this manner (wedged pressure) is present in the portal vein. The HVPG is the result of subtracting the suprahepatic vein pressure from the wedged pressure. HVPG is considered normal when it is less than 5 mm Hg. Subclinical portal hypertension exists if it is > 5 mm Hg and \< 10 mm Hg, and clinically significant if it is >10 mm Hg. HVPG is the best parameter predicting prognosis in patients with chronic liver diseases22, establishing the risk of complications and mortality, the response to treatment with beta-blockers, to antiviral agents, as well as evaluating the risk of liver failure after surgery for hepatocellular carcinoma19,23. However, this technique is only available in a few centers, uses ionizing radiation, is invasive, and does not accurately determine the actual pressure in the portal vein, making it not useful in cases of presinusoidal portal hypertension19.

Endoscopic ultrasound allows for direct pressure measurements in the suprahepatic vein and the portal vein, providing an accurate measurement of the portal pressure gradient (PPG). Comparative studies in animal models have shown comparable values between simultaneous determination of HVPG by interventional radiology and ultrasound-guided endoscopy24. Preliminary studies in humans, particularly in cirrhotic patients, have demonstrated its safety and accuracy, enabling the measurement of PPG and liver biopsy to be performed in the same endoscopic session25,26,27,28,29. A prospective, observational, multicenter study is registered in Clinical Trials (NCT04668664), currently recruiting, evaluating the efficacy and safety of PPG measurement obtained by endoscopic ultrasound in cirrhotic patients referred for upper gastrointestinal endoscopy or endoscopic ultrasound. This approach allows for a simplified assessment of the benefits of NSBB during a single invasive procedure and advances personalized therapy.

03

Conditions studied

  • Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS)
  • Hepatic Cirrhosis

Browse trials for

Keywords

  • Portal pressure gradient (PPG), endoscopic ultrasound (EUS) ,.the acute hemodynamic response
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients attending the hepatology clinic or hospitalized with a diagnosis of liver cirrhosis and an indication for primary prophylaxis with NSBBs will be prospectively and consecutively included

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with advanced liver disease with an indication for primary prophylaxis with NSBBs

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years. 2. Advanced stage hepatocellular carcinoma not eligible for curative treatment. 3. Pregnancy. 4. Esophageal stenosis. 5. > 1.5. 6. \< 50,000 µL. 7. Ascites. 8. Patients with any for performing an upper gastrointestinal endoscopy.
  1. Patients with contraindication to NSBB treatment. 10. Refusal to sign the form to participate in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No

Groups and cohorts

  • All patients attending the hepatology clinic or hospitalized with a diagnosis of liver cirrhosis

    All patients attending outpatient clinics or hospitalized with a diagnosis of viral etiology or alcohol-related liver cirrhosis will be evaluated for the indication of primary prophylaxis with NSBB according to Baveno VII guidelines. The choice of NSBB type was mainly based on clinical parameters, regardless of the presence of an acute hemodynamic response. In patients who did not show signs of circulatory dysfunction or refractory ascites, carvedilol was preferred, as it has been shown to be more potent in decreasing portal pressure. Carvedilol was initiated at a dose of 6.25 mg/day and, if tolerated, was subsequently increased to a target dose of 12.5 mg/day. Higher doses of carvedilol were only used in cases of concomitant hypertension. For propranolol users, the dose was progressively increased until the heart rate decreased to approximately 55 beats per minute. In patients with significant ascites, a maximum dose of 80 mg/day of propranolol was administered.

06

What researchers measure

Primary outcomes

  1. - Endoscopic ultrasound with determination of the portal venous pressure gradient using a 25G needle with adapted

    The portal pressure gradient (PPG) is obtained via transgastric, ultrasound-guided intraparenchymal hepatic puncture using a 25G needle (EchoTip Insight, Cook Medical®) equipped with a pressure gauge. Measurements are obtained in mm Hg. A puncture is made in the middle hepatic vein, and three pressure determinations are taken, each lasting one minute. The lowest observed pressure is recorded, and the mean is calculated. Subsequently, the left branch of the portal vein is punctured, and three measurements are taken, each lasting one minute, and their mean is calculated. The PPG is obtained by subtracting the mean pressures in the portal vein from the mean pressures in the hepatic vein. The pressure gauge recording the pressures is always fixed in the same position for all pressure measurements, positioned at the level of the patient's venous axis. After the initial hemodynamic assessment, propranolol (0.15 mg/kg of body weight; aqueous solution of propranolol hydrochloride \[1 mg/ml\] st

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — there is not a plan to make IPD available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2024; primary completion for Nov 2026, 24 months later.

Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 24 months is below that.

Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Oct 29, 2024
StartEst.
Nov 1, 2024
Primary completionEst.
Nov 1, 2026
CompletionEst.
Nov 1, 2027
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06664307
Lead sponsor
Hospital Universitario Virgen Macarena
Responsible party
Lourdes Grande Santamaría (ESPECIALISTA DE APARATO DIGESTIVO, Hospital Universitario Virgen Macarena) — Principal investigator
First posted
Oct 29, 2024
Start date
Nov 1, 2024 (estimated)
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Oct 29, 2024

Study contacts

LOURDES LGS GRANDE SANTAMARIA, DOCTOR
Contact
lourdes.grande.sspa@juntadeandalucia.es
+34 695919735
ENRIQUE E SILVA ALBARELLOS, RESIDENTE
Contact
+34 622012615
RAFAELR R ROMERO CASTRO, DOCTOR
study director · SAS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion